Saxenda and other glucagon-like peptide-1 (GLP-1) receptor agonists face charges in a consolidated lawsuit under MDL 3094. The plaintiffs are claiming that the manufacturers of these medications failed to inform them about how these can cause health conditions such as gastroparesis, vision loss, bowel obstruction, ileus, and persistent vomiting.
Novo Nordisk and Eli Lilly are two industry leaders in GLP-1 RAs, and they are now facing over 1,300 lawsuits in MDL 3094.
If you've been diagnosed with any of the severe conditions linked to Saxenda or other GLP-1 RA medications, don't hesitate to reach out to us. Our team of experts will check your case thoroughly and see if you're a potential claimant. If you are, we will refer you to an expert attorney who will file a Saxenda claim on your behalf.